☆ 4.6 Article

Cerebral venous thrombosis and portal vein thrombosis: A retrospective cohort study of 537,913 COVID-19 cases

ECLINICALMEDICINE (2021)

Related references

Note: Only part of the references are listed.

Review Clinical Neurology

Cerebral venous thrombosis and severe acute respiratory syndrome coronavirus-2 infection: A systematic review and meta-analysis

Tommaso Baldini et al.

Summary: This study identified a low number of cases of CVT associated with COVID-19, with symptoms mainly occurring after respiratory disease and involving multiple sites. The occurrence rate of CVT in hospitalized patients with COVID-19 is low but requires a high level of suspicion, as diagnosing this potentially life-threatening condition in COVID-19 patients can be challenging.

EUROPEAN JOURNAL OF NEUROLOGY (2021)

Add to Collection

Article Medicine, General & Internal

US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021

Isaac See et al.

Summary: Cases of CVST with thrombocytopenia following Ad26.COV2.S vaccination have been reported in the US, leading to serious outcomes. This case series may provide guidance for clinical management and further investigation into the potential relationship between Ad26.COV2.S vaccine and CVST with thrombocytopenia.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Medicine, General & Internal

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

Nina H. Schultz et al.

Summary: This study reports five cases of venous thrombosis and thrombocytopenia occurring 7 to 10 days after receiving the ChAdOx1 nCoV-19 vaccine, suggesting a rare vaccine-induced immune thrombotic thrombocytopenia. The condition, which can lead to catastrophic outcomes such as cerebral venous sinus thrombosis, may be treated with intravenous immune globulin.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Editorial Material Medicine, General & Internal

SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia

Douglas B. Cines et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Andreas Greinacher et al.

Summary: After vaccination with ChAdOx1 nCov-19, rare immune thrombotic thrombocytopenia can occur due to platelet-activating antibodies against PF4, resulting in various thrombotic events. Most patients in this case series were women, with fatal outcomes such as cerebral venous thrombosis and intracranial hemorrhage. Additional studies are needed to further investigate and understand this phenomenon.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study

Anton Pottegard et al.

Summary: This study assessed rates of cardiovascular and haemostatic events in Denmark and Norway after vaccination with the Oxford-AstraZeneca vaccine ChAdOx1-S, finding increased rates of venous thromboembolic events among recipients. Despite slightly higher rates of thrombocytopenia/coagulation disorders and bleeding, the overall safety outcomes were largely reassuring.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Psychiatry

6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records

Maxime Taquet et al.

Summary: Our study provides evidence of significant neurological and psychiatric morbidity in the 6 months following COVID-19 infection. The risks were highest in patients with severe COVID-19. This information could assist in service planning and research priority identification.

LANCET PSYCHIATRY (2021)

Add to Collection

Article Immunology

Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19

Aldo Bonaventura et al.

Summary: The authors suggest that SARS-CoV-2 infection induces a prothrombotic state and dysregulated immunothrombosis, leading to severe manifestations of COVID-19. They also discuss potential antithrombotic and immunomodulating drugs for treating COVID-19 patients, aiming to reduce the acute and long-term consequences of the disease by targeting immunothrombosis.

NATURE REVIEWS IMMUNOLOGY (2021)

Add to Collection

Letter Gastroenterology & Hepatology

Acute Portal Vein Thrombosis in SARS-CoV-2 Infection: A Case Report

Vincenzo La Mura et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2020)

Add to Collection

Editorial Material Gastroenterology & Hepatology

Gastric ischemia and portal vein thrombosis in a COVID-19-infected patient

See-Wei Low et al.

ENDOSCOPY (2020)

Add to Collection

Article Clinical Neurology

Trends in incidence and epidemiologic characteristics of cerebral venous thrombosis in the United States

Fadar Oliver Otite et al.

NEUROLOGY (2020)

Add to Collection

Letter Hematology

Portal vein thrombosis in a patient with COVID-19

A. Franco-Moreno et al.

THROMBOSIS RESEARCH (2020)

Add to Collection

Article Gastroenterology & Hepatology

Acute portal vein thrombosis secondary to COVID-19: a case report

Roham Borazjani et al.

BMC GASTROENTEROLOGY (2020)

Add to Collection

Review Clinical Neurology

Cerebral venous thrombosis

Suzanne M. Silvis et al.

NATURE REVIEWS NEUROLOGY (2017)

Add to Collection

Editorial Material Medicine, General & Internal

The Propensity Score

Jason S. Haukoos et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)

Add to Collection

© Peeref 2019-2024. All rights reserved.